Compare Novavax Inc (NVAX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Wix.Com Ltd — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Wix.Com Ltd trades at $68.86 (market cap $2.79B). The key difference: Wix.Com Ltd is far larger — about 2.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| NVAX | WIX | |
|---|---|---|
Market Cap | $1.31B | $2.79B |
Sector | Health | Technology |
52-Week High | $11.19 | $184.24 |
52-Week Low | $6.22 | $40.43 |
Enterprise Value | $889.30M | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
WIX stock trades at $68.78, up 10.18% today, with a bullish technical signal from moving averages. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19%, and the company faces a securities class action. The P/E ratio is elevated at 62.84, indicating high growth expectations. Recent news highlights the launch of Symphony by Wix, an AI system for SMBs, amidst legal challenges.
The outlook is mixed: strong analyst consensus (65.85% buy rating) and a $79.75 price target suggest upside, but legal risks and negative cash flow in 2025 pose significant headwinds. Investors should weigh growth potential against execution and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
